1984, 1986). α1-PI, one of the most important inhibitors of GE was found to be present in an inactive state. In this study, we asked the question whether in CF bronchial secretions α1-PI is ...

Currently, the company’s portfolio includes PAT-1251, a phase 2-ready LOXL2 inhibitor for the treatment of idiopathic pulmonary, liver and kidney fibrosis, and PAT-409, a phase 1-ready ATX ...